FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293686761> ?p ?o ?g. }

• W4293686761 endingPage "2130" @default.
• W4293686761 startingPage "2130" @default.
• W4293686761 abstract "Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on the efficacy and safety in clinical practice of infliximab (CT-P13) in subcutaneous formulation (SC) for the treatment of patients with IBD. Methods: Multicenter, prospective study of patients with IBD in clinical remission, who had their treatment changed from intravenous (IV) infliximab to SC. Two groups of patients were evaluated according to whether they were on IV infliximab treatment at standard or intensified doses before the switch. Results: A total of 30 patients were on standard dosing and another 30 in intensified therapy. Treatment persistence in both groups at 6 months was greater than 95%. In both groups after the change, neither the biomarkers of inflammation nor the activity indices underwent significant changes at 3 and 6 months compared to the baseline value. Similarly, in both groups, infliximab trough levels showed a significant increase 3 and 6 months after the change to SC. No serious adverse events were registered. Conclusions: The CT-P13 SC brings a new anti-TNF era. Achieving much higher drug levels that are constant over time opens new paths to explore the management of patients with IBD: less immunogenicity, better perianal disease control and higher achievement of mucosal healing." @default.
• W4293686761 created "2022-08-31" @default.
• W4293686761 creator A5007318844 @default.
• W4293686761 creator A5011321206 @default.
• W4293686761 creator A5012997037 @default.
• W4293686761 creator A5023730578 @default.
• W4293686761 creator A5025413267 @default.
• W4293686761 creator A5037699873 @default.
• W4293686761 creator A5042715991 @default.
• W4293686761 creator A5048774215 @default.
• W4293686761 creator A5073600422 @default.
• W4293686761 creator A5077901585 @default.
• W4293686761 creator A5080436362 @default.
• W4293686761 creator A5089787452 @default.
• W4293686761 date "2022-08-30" @default.
• W4293686761 modified "2023-10-18" @default.
• W4293686761 title "Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study" @default.
• W4293686761 cites W1979948289 @default.
• W4293686761 cites W1986079650 @default.
• W4293686761 cites W2022661087 @default.
• W4293686761 cites W2031193040 @default.
• W4293686761 cites W2042314018 @default.
• W4293686761 cites W2061154423 @default.
• W4293686761 cites W2079295802 @default.
• W4293686761 cites W2195373199 @default.
• W4293686761 cites W2334673652 @default.
• W4293686761 cites W2463061385 @default.
• W4293686761 cites W2528535517 @default.
• W4293686761 cites W2574762966 @default.
• W4293686761 cites W2726676976 @default.
• W4293686761 cites W2734612724 @default.
• W4293686761 cites W2914716166 @default.
• W4293686761 cites W2938255449 @default.
• W4293686761 cites W2945268218 @default.
• W4293686761 cites W2966028626 @default.
• W4293686761 cites W2968785269 @default.
• W4293686761 cites W2978880955 @default.
• W4293686761 cites W2996966237 @default.
• W4293686761 cites W3134678138 @default.
• W4293686761 cites W3190445083 @default.
• W4293686761 cites W3200096105 @default.
• W4293686761 cites W3203871149 @default.
• W4293686761 cites W4200004408 @default.
• W4293686761 cites W4200411569 @default.
• W4293686761 cites W4206907054 @default.
• W4293686761 cites W4206924027 @default.
• W4293686761 cites W4214642973 @default.
• W4293686761 cites W4220886472 @default.
• W4293686761 cites W4225363052 @default.
• W4293686761 cites W4292341189 @default.
• W4293686761 doi "https://doi.org/10.3390/biomedicines10092130" @default.
• W4293686761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36140230" @default.
• W4293686761 hasPublicationYear "2022" @default.
• W4293686761 type Work @default.
• W4293686761 citedByCount "3" @default.
• W4293686761 countsByYear W42936867612023 @default.
• W4293686761 crossrefType "journal-article" @default.
• W4293686761 hasAuthorship W4293686761A5007318844 @default.
• W4293686761 hasAuthorship W4293686761A5011321206 @default.
• W4293686761 hasAuthorship W4293686761A5012997037 @default.
• W4293686761 hasAuthorship W4293686761A5023730578 @default.
• W4293686761 hasAuthorship W4293686761A5025413267 @default.
• W4293686761 hasAuthorship W4293686761A5037699873 @default.
• W4293686761 hasAuthorship W4293686761A5042715991 @default.
• W4293686761 hasAuthorship W4293686761A5048774215 @default.
• W4293686761 hasAuthorship W4293686761A5073600422 @default.
• W4293686761 hasAuthorship W4293686761A5077901585 @default.
• W4293686761 hasAuthorship W4293686761A5080436362 @default.
• W4293686761 hasAuthorship W4293686761A5089787452 @default.
• W4293686761 hasBestOaLocation W42936867611 @default.
• W4293686761 hasConcept C126322002 @default.
• W4293686761 hasConcept C141071460 @default.
• W4293686761 hasConcept C197934379 @default.
• W4293686761 hasConcept C2775862500 @default.
• W4293686761 hasConcept C2776390293 @default.
• W4293686761 hasConcept C2777138892 @default.
• W4293686761 hasConcept C2777288759 @default.
• W4293686761 hasConcept C2778260677 @default.
• W4293686761 hasConcept C2779134260 @default.
• W4293686761 hasConcept C2779280984 @default.
• W4293686761 hasConcept C2780479503 @default.
• W4293686761 hasConcept C535046627 @default.
• W4293686761 hasConcept C71924100 @default.
• W4293686761 hasConcept C90924648 @default.
• W4293686761 hasConceptScore W4293686761C126322002 @default.
• W4293686761 hasConceptScore W4293686761C141071460 @default.
• W4293686761 hasConceptScore W4293686761C197934379 @default.
• W4293686761 hasConceptScore W4293686761C2775862500 @default.
• W4293686761 hasConceptScore W4293686761C2776390293 @default.
• W4293686761 hasConceptScore W4293686761C2777138892 @default.
• W4293686761 hasConceptScore W4293686761C2777288759 @default.
• W4293686761 hasConceptScore W4293686761C2778260677 @default.
• W4293686761 hasConceptScore W4293686761C2779134260 @default.
• W4293686761 hasConceptScore W4293686761C2779280984 @default.
• W4293686761 hasConceptScore W4293686761C2780479503 @default.
• W4293686761 hasConceptScore W4293686761C535046627 @default.
• W4293686761 hasConceptScore W4293686761C71924100 @default.
• W4293686761 hasConceptScore W4293686761C90924648 @default.

• next